Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 272 matching trials from the live ClinicalTrials.gov search.
Conditions
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Interventions
Atezolizumab, Biospecimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Tocilizumab
Biological · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
110
States / cities
Anaheim, California • Bellflower, California • Los Angeles, California + 89 more
Conditions
Heart Failure, Heart Failure, Systolic
Interventions
Pharmacist/Cardiologist Virtual Team Digital Consultation
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Multiple Myeloma
Interventions
Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 3 more
Conditions
Prostate Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
COVID-19 Pneumonia
Interventions
Placebo, Tocilizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • El Centro, California + 28 more
Conditions
Healthy Volunteer
Interventions
AI-1000 G2, PFS-NSD, Tocilizumab
Device · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Lenexa, Kansas • Marlton, New Jersey • Salt Lake City, Utah
Conditions
Covid19, Urine, Biomarker, Acute Respiratory Failure With Hypoxia
Interventions
Not listed
Lead sponsor
National Center for Global Health and Medicine, Japan
Government
Eligibility
20 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Anxiety Depression, Aneurysm Cerebral, Mental Health Wellness 1
Interventions
Clipping, Endovascular embolization, Surveillance imaging
Procedure · Diagnostic Test
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Intracranial Arterial Aneurysm
Interventions
Additional scan time on standard MR angiography
Radiation
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Burlington, Massachusetts
Conditions
Sickle Cell Disease, Acute Chest Syndrome
Interventions
Tocilizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Congenital Heart Disease
Interventions
Gadopiclenol, Gadobenate dimeglumine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 81 more
Conditions
Rheumatoid Arthritis
Interventions
Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
76
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 71 more
Conditions
Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Interventions
Tocilizumab
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
8
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 5 more
Conditions
Glucocorticosteroid Refractory Acute GVHD
Interventions
Toclizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Study of Tocilizumab to Treat Polymyalgia Rheumatica

NCT01396317
Conditions
Polymyalgia Rheumatica (PMR)
Interventions
Tocilizumab
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
Interventions
Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
10
States / cities
Birmingham, Alabama • Fresno, California • Jacksonville, Florida + 6 more
Conditions
Multiple Myeloma
Interventions
Ramantamig, Tocilizumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Goodyear, Arizona • Beverly Hills, California • Irvine, California + 2 more
Recruiting No phase listed Observational Accepts healthy volunteers

Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)

NCT05865054
Conditions
Giant Cell Arteritis
Interventions
Magnetic Resonance Imaging (MRI)
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2033
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Completed Not applicable Interventional Results available

Bevacizumab w / Temozolomide PET & Vascular MRI For GBM

NCT01987830
Conditions
Recurrent Glioblastoma
Interventions
MRI-PET, TMZ-PET
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
B-Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions
Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
Conditions
COVID-19 Pneumonia
Interventions
Remdesivir, Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more
Not listed Phase 1 Interventional

Tocilizumab in Schizophrenia

NCT02874573
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Tocilizumab, Normal saline
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Augusta, Georgia